May 22,2020 | New Longer-Term Safety Data of Chugai’s Satralizumab in Adults and Adolescents with Neuromyelitis Optica Spectrum Disorder Presented at EAN | News | CHUGAI PHARMACEUTICAL CO., LTD.

TOKYO, May 22, 2020 — Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a press release regarding the new longer-term safety data of satralizumab (development code: SA237) for the treatment of adults and adolescents with neuromyelitis optica spectrum disorder presented at the 6th Annual Meeting of the European Academy of Neurology. Satralizumab is an anti-IL-6 receptor recycling antibody created by Chugai.

Please refer to the link below for details of the press release:

Related:  May 29,2020 | Updated Data of Overall Survival and Safety from the ALEX Study for Chugai's Alecensa Presented at the 2020 American Society of Clinical Oncology (ASCO) | News | CHUGAI PHARMACEUTICAL CO., LTD.

See More News From:
View all companies covered in the Company A-Z List